You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,421,278

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,421,278

Title:	Duocarmycin ADCS showing improved in vivo antitumor activity
Abstract:	The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumors with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
Inventor(s):	Dokter; Willem (Nijmegen, NL), Goedings; Peter Johannes (Nijmegen, NL), Verheijden; Gijsbertus Franciscus Maria (Nijmegen, NL), Beusker; Patrick Henry (Nijmegen, NL)
Assignee:	Synthon Biopharmaceuticals B.V. (Nijmegen, NL)
Application Number:	14/859,201
Patent Claims:	1. A method of treating triple negative breast cancer in a human patient, comprising administering to the patient a therapeutically effective amount of a compound having the structure ##STR00011## wherein 2.5-2.9 represents an average DAR for the compound. 2. The method of claim 1, wherein the average DAR for the compound is from 2.6 to 2.9. 3. The method of claim 1, wherein the compound is administered in an amount of from about 0.3 mg/kg to about 10 mg/kg. 4. The method of claim 3, wherein the compound is administered every three weeks. 5. The method of claim 1, further comprising administering an effective amount of a therapeutic antibody or a chemotherapeutic agent, or a combination thereof. 6. The method of claim 5, wherein the therapeutic antibody is pertuzumab and the chemotherapeutic agent is a taxane or an anthracycline. 7. The method of claim 6, wherein the taxane is docetaxel or paclitaxel, and the anthracycline is doxorubicin, epirubicin, daunorubicin or valrubicin. 8. The method of claim 1, wherein the patient is administered a pharmaceutical composition, comprising the compound as defined in claim 1 and one or more pharmaceutically acceptable excipients. 9. The method of claim Si, wherein the pharmaceutical composition is suitable for intravenous infusion. 10. The method of claim 8, wherein the pharmaceutical composition is in the form of a lyophilized powder or a frozen solution.

Details for Patent 9,421,278

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012	⤷ Try a Trial	2034-01-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.